“We would like to use all of what we've learned in the MAPP to move back into the space of clinical trials and trying to identify effective therapies for this condition,” says Alisa J. Stephen-Shields, PhD.
In this video, Alisa J. Stephens-Shields, PhD, discusses future research following up on the Journal of Urology study, “Clinically Important Differences for Pain and Urinary Symptoms in Urologic Chronic Pelvic Pain Syndrome: A MAPP Network Study.” Stephens-Shields is an associate professor of biostatistics, epidemiology, and informatics at the University of Pennsylvania Perelman School of Medicine in Philadelphia.
We would like to use all of what we've learned in the MAPP to move back into the space of clinical trials and trying to identify effective therapies for this condition. We now have a better sense of what the end points are that we should look at in our trials. We have a better sense of the types of patients that should be recruited into these trials, and using this research as far as how to identify meaningful change is an important aspect of identifying a responder to a therapy. So the next step in this, broadly speaking, is to go back to the therapeutic trials, but now we can design much better trials that are much more likely to have positive findings with regard to effective therapies, and we know how to identify and define responders in these trials based on this research. So I would say the next steps are, let's conduct these trials.
This transcription was edited for clarity.